The abstract submission system is now open!
Abstract submission deadlines
Abstracts Trial in Progress Intent to submit LBA |
Tuesday, 16 July 2024 18:00 SGT (Local Singapore Time) 12:00 CEST (Central European Summer Time)
|
Late-breaking abstracts (LBA) |
Tuesday, 8 October 2024 18:00 SGT (Local Singapore Time) 12:00 CEST (Central European Summer Time) A skeleton indicating the type of data that will be available by the late-breaking abstract deadline must be submitted online by the regular abstract deadline of 16 July 2024 |
Outcome notifications
Outcome notifications are expected to be made available to first authors and submitters by mid-September 2024.
Outcome notifications of accepted full LBAs are expected to be made available to first authors and submitters by mid-October 2024.
Information for presenters
Detailed instructions for the preparation of slide presentations and/or posters will be made available on the ESMO website by mid-September 2024, in the section “Information for Presenters”.
Abstract submission categories
Breast cancer, early stage |
Head and neck cancer, excluding thyroid |
Breast cancer, locally advanced |
Palliative care |
Breast cancer, metastatic |
Precision medicine |
Developmental therapeutics |
Supportive care |
Gastrointestinal tumours, colorectal |
Thoracic tumours, early stage |
Gastrointestinal tumours, non-colorectal |
Thoracic tumours, locally advanced |
Genitourinary tumours, prostate |
Thoracic tumours, metastatic |
Genitourinary tumours, non-prostate |
Miscellaneous |
Gynaecological cancers |
|
Late-breaking abstracts (LBA)
Late-breaking abstracts may be submitted for high quality, new research findings from randomised phase II or phase III trials with implications for clinical practice or understanding of disease processes.
The final late-breaking abstract deadline of 8 October 2024 is under no circumstances to be considered as an extension of the general submission deadline (16 July 2024).
Trial in progress abstracts (TiP)
Trial in Progress (TiP) abstracts in all phases of clinical research (phases I to III) may be submitted to the ESMO Asia Congress 2024.
It is expected that abstracts submitted as Trial in Progress are ongoing trials that have not reached any protocol-specified endpoints for analysis.
Young Oncologist (YO) Patient case studies
Challenging clinical case studies in the new era of personalised medicine may be submitted by young oncologists under 40 years of age.
Presentation and publication of accepted abstracts
The ESMO Asia 2024 Scientific Committee will select abstracts for presentation during the Congress based on the following possibilities:
- Presidential Symposium – Oral presentations by authors presenting cutting-edge and significant clinical practice-changing studies, followed by expert discussion and perspectives.
- Proffered Paper – Oral presentations by authors presenting original data of superior quality, followed by expert discussion and perspectives.
- Mini Oral – Short oral presentations by authors presenting data of good quality, followed by expert discussion and perspectives.
- Poster – Display session for review, discussion and questions. The presenting authors must be available for Q&A to represent their work.
All accepted abstracts, including late-breaking abstracts, will be published online only in the ESMO Asia Congress 2024 Abstract Book, a supplement to the official ESMO journal, Annals of Oncology.
Publication schedule of accepted abstracts
Details regarding the publication of accepted abstracts will be available here.
ESMO Merit Travel Grants
A limited number of Merit Travel Grants to the ESMO Asia Congress 2024 are available, upon application, to first authors who submit abstracts considered deserving of recognition. Candidates must be ESMO members under the age of 40 (forty). Selection will be made by the ESMO Asia Congress 2024 Scientific Committee on a competitive basis from among the accepted abstracts.